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Abstract. Analog-sensitive (AS) kinases contain large to small mutations in the gatekeeper 
position rendering them susceptible to inhibition with bulky analogs of pyrazolopyrimidine-
based Src kinase inhibitors (e.g. PP1). This ‘bump-hole’ method has been utilized for at least 
85 of ~520 kinases, but many kinases are intolerant to this approach. To expand the scope of 
AS-kinase technology, we designed type II kinase inhibitors, ASDO2/6 (Analog-Sensitive 
‘DFG-Out’ kinase inhibitors-2/6), that target the ‘DFG-out’ conformation of cysteine (Cys)-
gatekeeper kinases with submicromolar potency. We validated this system in vitro against 
Greatwall kinase (GWL), Aurora-A kinase and Cyclin-dependent kinase-1 and in cells using 
M110C-GWL expressing mouse embryonic fibroblasts. These Cys-gatekeeper kinases were 
sensitive to ASDO2/6-inhibition, but not AS-kinase inhibitor 3MB-PP1 and vice versa. These 
compounds, with AS-kinase inhibitors, have the potential to inhibit multiple AS-kinases 
independently with applications in systems level and translational kinase research as well as 
the rational design of type II kinase inhibitors targeting endogenous kinases. 
 
Overview of kinases and analog-sensitive kinase technology. Eukaryotic protein kinases 
represent one of the largest protein families in the human genome with ~520 members and 
constituting about 2% of all human genes1. These enzymes catalyze the transfer of the -
phosphate group from ATP to serine (Ser), threonine (Thr) or tyrosine residues on their 
substrate proteins or peptides. This post-translational modification is a critical and nearly 
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ubiquitous mode of intracellular signaling, with about 30% of all proteins being 
phosphorylated2, 3. It is, therefore, to no surprise that aberrant expression and activation of this 
class of proteins often leads to a variety of diseases with about 244 kinases mapping to 
disease loci and cancer amplicons1, 4, 5. 
 
One way to study kinase function and manage dysregulated kinases is through development 
of selective kinase inhibitors; however, due to the high degree of structural similarity, 
particularly in and around the ATP-binding pocket, it is often difficult to target an individual 
kinase with small-molecule inhibitors. One way to circumvent this issue is by employing a 
chemical-genetic strategy that takes advantage of a structurally conserved, mostly 
hydrophobic residue within the kinase active-site, termed the gatekeeper residue6-8. Mutation 
of this residue from a normally bulky residue to a smaller one, such as alanine (Ala) or glycine 
(Gly), engenders an analog-sensitive (AS) kinase containing a unique binding-site that can be 
exploited pharmacologically with bulky ATP-analogs such as 1NM-PP18, 3MB-PP18 and the 
recently developed staralogs7 (Figure 1A-D). This ‘bump-hole’ method has been utilized for 
the study of at least 85 different kinases, yet despite this level of success there are still a 
number of kinases, coined ‘intolerant’ kinases, that do not tolerate gatekeeper mutations8-11. 
To expand the scope of AS-technology, researchers have identified second-site mutations, or 
suppressor of Gly gatekeeper mutations (sogg), that restore the kinase activity to some 
‘intolerant’ AS-kinases (applied to at least 11 kinases so far) when the gatekeeper is Gly or 
Ala8, 10. In addition, electrophile-sensitive (ES)-kinases can be selectively inhibited by 
electrophilic, bulky PP1- or ATP-analogs (Figure 1E) (e.g. fluoromethylketobenzyl (FMKB)-
PP1, acrylamido-anilinoquinazolines (AQZ) and 5’-vinylsulfonyl adenosine (VSA)) by targeting 
cysteine (Cys)-mutations within the gatekeeper or other positions vicinal to the ATP-binding 
pocket (i.e. in the Gly-rich loop (G-loop) or hinge region, Figure 1A)9, 12-18 . However, these 
approaches appear to be highly specific to individual kinases and not widely applicable. This 
also limits the possibility to differentially inhibit two kinases with two orthogonal chemical 
genetic systems. Such a dual bio-orthogonal approach would be ideal for investigating kinase 
signaling crosstalk, synthetic lethality and many other areas of systems biology and 
translational research across a diverse set of kinase drug targets.  
 
In this study, we report the development of a new chemical-genetic approach based on a Cys-
gatekeeper mutation and non-covalent, type II mode of kinase inhibition that targets the 
inactive “DFG-out” kinase conformation (Figure 1C)19. We verified this approach with three 
divergent Ser/Thr-kinases: Greatwall kinase (GWL), Aurora-A kinase (AAK) and Cyclin-
dependent kinase-1 (Cdk1). To demonstrate compound efficacy in cells, we measured 
phosphorylation of the physiologic GWL substrate -endosulfine (ENSA)20 and cellular 
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proliferation, a phenotype functionally linked to GWL activity21, 22, in wild type (WT)- and 
M110C (MC)-GWL expressing mouse embryonic fibroblasts (MEFs). ASDO2 (Analog-
Sensitive “DFG-Out” kinase inhibitor-2) specifically inhibited production of phospho-ENSA 
(pENSA) and attenuated proliferation in MC-GWL expressing MEFs, but not in WT-GWL 
expressing cells. Together, these data support expanding the AS-kinase inhibitor tool set with 
“DFG-out” targeting ASDO inhibitors, which in combination allow for the independent targeting 
of at least two distinct kinases (Figure 1C). 
 
RESULTS AND DISCUSSION 
 
Approaches utilized to expand analog-sensitive kinase technology. The starting 
point of this study was an effort to develop an AS-version of microtubule-associated Ser/Thr 
kinase-like (MASTL) protein, commonly known as GWL, in order to investigate its mitotic 
functions and role in the cell cycle23. Over-expression and immunoprecipitation of FLAG-
tagged GWL constructs provided a means to assess the activity of a cohort of GWL mutants 
(Figure 2A). This assay demonstrated that GWL is an ‘intolerant’ kinase evidenced by the 
inactivity of the AS1 (M110G) and AS2 (M110A) GWL kinase alleles (Figures 2B-C & S1A), 
and neither sogg mutations nor the ES-kinase approach were capable of generating an AS-
GWL system (Figure S1A-G). In the first instance, we decided to make sogg mutations at the 
analogous positions in GWL, which included mutations that were previously successful for 
kinases such as Pto (L68I), APH(3’)-IIIa (N268T) and GRK2 (S268V) (Figure S1G)10. Only 
one of these mutations, V61I-GWL, augmented GWL activity, evidenced by increased myelin 
basic protein phosphorylation, but did not restore activity of the double mutant V61I/M110A-
GWL (Figure S1B). Bioinformatically, we identified sites in the G-loop consensus sequence 
(GxGxxG) that deviated from other AGC kinases, but reversion mutations in the G-loop, made 
to adopt the more common amino acids, had a meagre (S42G) to no (S42G/A45S) effect in 
combination with M110A-GWL (Figure S1, panels A & C)24. 
 
Initial efforts to identify sogg mutations for Ala-gatekeeper GWL were unsuccessful, and thus 
we hypothesized that other small amino acids, presumably preserving an expanded 
hydrophobic ATP-binding pocket, might be useful in combination with previously identified or 
new sogg mutations. To explore this idea further, the gatekeeper position was scanned with 
relatively small amino acids, which led to the discovery that MC-GWL-mediated 
phosphorylation of ENSA was only 4-fold less compared to WT (Figure 2B-C). Furthermore, 
through FACS analysis, we showed that RNAi-resistant MC-GWL, unlike M110A-GWL, was 
able to restore G1, S and G2/M cellular levels to the same extent as an siRNA-resistant WT 
rescuing plasmid in GWL depleted HeLa cells (Figures 2D-I & S2A-F). This result inspired the 
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generation of an ES-kinase system; however, the electrophilic inhibitors AG1-2 and FMKB-
PP1 (Figures 1E, S1D-E & S2), which were validated against T338C-c-Src, did not robustly 
inhibit MC-GWL at 20 M concentrations (Figure S1D-E)9. Of the other small gatekeeper 
mutations, M110T-GWL displayed ~8% activity compared to WT, and thus we made Cys 
mutations in an M110T-GWL mutant to mimic the cysteines in the hinge regions of EphB3 
(C717) and EGFR (C797); M110T/G116C and M110T/D117C13, 15. In combination with a Thr 
gatekeeper, similar mutations in EphB1 (G703C) and c-Src (S345C), to name a few, are 
targetable using electrophilic quinazoline-based inhibitors (e.g. AQZ, Figure 1D), but due to 
the inactivity of these GWL double mutants, we were not able to apply them (Figure S1F-G)13, 
15. 
 
AD57-analogs specifically target MC-GWL in vitro. Due to the inefficacy of known ES-
kinase inhibitors against MC-GWL, we decided to generate novel inhibitors based on the 
structure of AD5725 (Figures 3A & S3). We surmised that replacement of the urea linker with 
an acrylamide linker might allow selective targeting by a nucleophilic Cys-mutant16. AD57 also 
seemed like an ideal candidate as it selectively inhibited MC-GWL with an IC50 value of 10.6 
± 0.4 M and displayed no inhibitory activity against WT-GWL (Figure 3, panels B & D). 
ASDO1, the first in a series of AD57-analogs, was synthesized by coupling of an 
anilinopyrazolopyrimidine with a 3-benzoylacrylic acid chloride (Supplemental Schemes 1–3 
& Figure 4A)9, 26. The resulting compound contained an acrylamide linker bridging the 
pyrazolopyrimidine moiety with a trifluoromethylbenzoyl group. This feature is similar to a 
trifluoromethylphenyl group, which is commonly incorporated into some type II kinase 
inhibitors19, 27. ASDO1 (Analog-Sensitive “DFG-Out” kinase inhibitor-1) (Figure 3A) completely 
abrogated MC-GWL activity at a concentration of 20 M without inhibiting WT-GWL (Figure 
S3). By assaying AD57 and ASDO1 more rigorously using the immunoprecipitation-based 
kinase assay with ENSA as substrate, we were able to show that ASDO1 exhibited a >60-fold 
improvement in potency against MC-GWL with an IC50 value of 0.17 ± 0.09 M and remained 
exquisitely selective for MC- vs. WT-GWL even up to concentrations as high as 100 M 
(Figures 3C-D, 4A & S4A-B).     
 
Structural studies using an AD57-c-Src co-crystal structure predicted that formal halogenation 
of the terminal phenyl ring with ortho-fluorine and para-chlorine substituents would fine-tune 
the selectivity profile of AD57. Indeed, these halogenated AD57-derivatives maintained 
inhibitory activity toward Ret, Raf, Src and S6K, reduced mTor inhibition and led to significantly 
less toxicity in a multiple endocrine neoplasia type 2 Drosophila model system25. In an attempt 
to fine-tune the selectivity of ASDO1 toward MC- vs. WT-GWL, we synthesized halogenated 
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and bulkier, non-halogenated ASDO-derivatives by first incorporating acetophenones into the 
microwave-assisted aldol-condensation with glyoxylic acid to yield 3-benzoylacrylic acids26, 
which after conversion to acid chlorides were later coupled with anilinopyrazolopyrimidines 
(Supplemental Schemes 2–3 & Figure 4A) to produce ASDOs 2 – 6. 
 
ASDO2 contains a trifluoromethylbenzoyl group with a para-fluoro substituent and 
demonstrated an ~3-fold improvement in potency, whereas the effect of the para-chloro 
substitution (ASDO3) was negligible (Figures 4A-C & S4C-E). We also explored the activity of 
bulkier derivatives in hopes of improving their selectivity for Cys-gatekeeper versus WT 
kinases. Unfortunately, replacing the central benzene ring with a naphthyl (ASDO4, Figures 
4A & S4F) or 3-methylbenzyl group (ASDO5, Figures 4A & S4G) dramatically weakened 
inhibitory activity; however, the 2-methylphenyl substitution of the inner-benzene ring 
(ASDO6) in combination with the para-fluoro substitution seen in ASDO2 resulted in a 
compound with inhibitory activity almost equal to that of the ASDO1 precursor (Figures 4A, C-
D & S4H-I). Interestingly, DO1, which lacks the pyrazolopyrimidine group, also displayed 
mono-specific targeting of MC-GWL vs. WT, but with attenuated inhibitory activity compared 
to ASDO1 (Figures 4A, C & S4J-K), suggesting that the selectivity filter resulting in Cys-
gatekeeper kinase specificity lies within the phenylbenzoylacrylamide scaffold and that the 
electrophilic olefin might be targeted by the Cys-gatekeeper residue. Furthermore, 
replacement of the trifluoromethyl group of DO1 with a para-ethoxy substituent (DO2) 
completely ablated inhibitory activity toward both WT- and MC-GWL (Figures 4A, C & S4L-
M). Interestingly, some type II kinase inhibitors (e.g. AD57 and Sorafenib25, 27) possess a 
trifluoromethyl substituent on their terminal phenyl ring, which occupies space in an allosteric 
hydrophobic pocket unique to the inactive kinase conformation19, 28. In contrast to DO1, the 
lack of inhibitory activity of DO2 hints at the possibility that this series of compounds, like the 
parent compound AD57, might stabilize the inactive ‘DFG-out’ kinase conformation. 
 
To establish the importance of the bulkier central ring of ASDO6, both ASDO2 & 6 were 
subjected to a rigorous kinase inhibition-profiling screen (International Centre for Kinase 
Profiling, University of Dundee Kinase Profiling Express Screen). At 1 M, ASDO2 inhibited 
15 of 50 kinases with inhibitory activity ≥ 60% (60–95%); however, as is the case with classical 
AS-kinase inhibitors, the increased bulk of the central benzene ring of ASDO6 likely accounts 
for the decrease in number of WT-kinases targeted with inhibitory activity  > 60% (62–84%); 
only 4 of 50 kinases. Note that the higher end of the inhibitory range decreased from 95% for 
ASDO2 to 84% for ASDO6, providing further evidence that the bulkier ASDO6-derivative is 
more refractory toward WT-kinases (Figures 4E & S5A-B). 
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ASDO6 targets AAK and Cdk1 bearing a Cys-gatekeeper. Next, we sought to place ASDO-
compounds within the pantheon of general AS-kinase inhibitors. To do this, we mutated the 
gatekeeper positions of AAK (L210) and Xenopus laevis Cdk1 (F80) to cysteines and 
subjected them to kinase assays with increasing concentrations of ASDO2 or 6 (Figures 5A-
F & S6A-C). Both kinases tolerated the Cys-gatekeeper mutation with improved (Cdk1) or a 
slight reduction (AAK) in kinase activity compared to WT (Figure S6B-C). Moreover, ASDO2 
inhibited L210C (LC)-AAK with the greatest potency, demonstrating an IC50 value of 25 ± 2 
nM (Figures 4A & 5, panels A & C) and was >70-fold selective in targeting LC-AAK vs. WT-
AAK. Although less potent than ASDO2, ASDO6 inhibition of LC-AAK (IC50 = 1.7 ± 0.4 M) 
and F80C-Cdk1 was about 10-fold more selective vs. their WT counterparts, respectively 
(Figure 5B-F). 
 
ASDO2 selectively inhibits MC-GWL in cells. Although ASDO6 inhibited less WT-kinases 
with inhibitory activity >60% (Figure 4E), ASDO2 displayed greater potency and specificity in 
GWL and AAK kinase assays (Figure 4A). We, therefore, opted to assess the effects of 
ASDO2 on cellular ENSA phosphorylation and proliferation in MEFs over-expressing WT- or 
MC-GWL. To establish cellular models for MC-GWL, we decided to employ MEFs containing 
loxP sites flanking exon 4 of the murine GWL gene29. Treatment of these cells with Cre-
expressing adenovirus depleted GWL and allowed for reintroduction of human WT- or MC-
GWL cDNA via lentiviral transduction (Figure 6A). After confirming the presence of human 
GWL by western analysis, both populations of WT- and MC-GWL expressing cells were 
treated with nocodazole (200 ng mL-1) for 16–20 h (Figure 6B). The activity of mitotic kinases 
increases substantially during mitosis, making the nocodazole-mediated mitotic arrest (M-
arrest) essential for visualizing the cellular inhibition of ENSA phosphorylation; inhibition of an 
inactive kinase would only reveal background level phosphorylation. After M-arrest and 4 h of 
2 M ASDO2 or DMSO treatment, cells were harvested, lysed and probed with anti-pENSA 
antibody by western blot analysis, revealing mono-specific inhibition of MC-GWL-mediated 
ENSA phosphorylation (Figure 6C-D). Functionally, GWL has been linked to cellular 
proliferation in several studies, and thus serves as an ideal gauge for GWL activity21, 22. After 
5 d of growth in the presence of inhibitor or DMSO, we observed that only cells depleted of 
endogenous WT-GWL and over-expressing MC-GWL had dramatically reduced proliferation 
in an ASDO2 concentration-dependent manner, thus confirming the utility of ASDO2 and 
possibly other ASDO-derivatives in cellular models (Figure 6E). 
 
ASDO2 displays relatively slow-on/slow-off binding/dissociation kinetics. At this point, 
it was still unclear how ASDO2/6 mono-specifically targeted MC- vs. WT-GWL (i.e. as a type 
 
 
7 
I or II inhibitor) and the presence of an electrophilic, doubly-activated olefin brings to question 
whether or not it interacts with MC-GWL in a reversible or irreversible manner. To further probe 
the mechanism of action of ASDO2, we investigated the reversibility of inhibition in comparison 
to a type I inhibitor (staurosporine) and the parent type II inhibitor AD57; note that type I 
inhibitors generally display fast-on/fast-off binding/dissociation kinetics, whereas type II 
inhibitors generally display  slow-on/slow-off binding/dissociation kinetics28, 30.  
 
Initially, a washout experiment with MC-GWL supported the notion of an ES-kinase model 
system. Evidence for this is seen by the failure of ASDO2-treated (10 M) MC-GWL to regain 
activity after 5 washes over a 4 h period compared to the quick reactivation of staurosporine 
(STP)-treated (50 M) MC-GWL under the same conditions (Figure 7A-C). However, when 
we probed reactivation of MC-GWL after longer periods of time following washout of ASDO2 
and AD57 (bona fide type II inhibitor), it became evident that MC-GWL regained activity over 
time, but this reactivation period took longer due to a relatively slower off-rate (Figure 7D-E). 
Importantly, activity may not have rebounded to levels demonstrated by fully active MC-GWL 
(not treated with inhibitor) due to decomposition or destabilization of the protein over a 24 h 
period at 4 oC. Additionally, ASDO2 rapidly inhibited MC-GWL activity, but with a slight 
difference in inhibitory activity between 20- and 60-minute compound pre-incubation periods 
(Figure 7F). Taken together, these data suggest that ASDO2 shares similar slow-on/slow-off 
binding/dissociation kinetics as the type II inhibitor AD57, but could also be acting, to a small 
extent, in an irreversible manner as inhibition marginally improves over time (Figure 7F). 
Unfortunately, expression, purification and X-ray crystallography of full-length GWL has 
proven to be a major technical challenge; therefore, to pin down the exact binding mode of 
ASDOs in GWL, technical innovations in GWL structural biology are required21.  
 
ASDO2/6 demonstrates a type II inhibitor binding mode with LC-AAK. To cement the 
binding-mode of ASDO2/6,  we solved X-ray co-crystal structures with LC-AAK: ASDO2 (PDB: 
6HJK) and ASDO6 (PDB: 6HJJ)31. Both compounds were sandwiched between the N- and C-
terminal lobes bound to the ATP-binding pocket, making the expected interactions with the 
backbone of the hinge region (Glu211 and Ala213) and stretching all the way to the C-helix, 
displacing it in comparison to the WT-AAK ADP-bound structure (PDB: 4CEG, Figure  S7A-
D). In both cases, the DFG-motif adopts an ‘out’ conformation (DFG-out), in which Phe275 
points into the ATP-binding pocket, while the terminal aromatic groups of both compounds are 
buried in a hydrophobic pocket adjacent to the C-helix, indicative of type II kinase inhibitors 
(Figures 8A-B & S7D)19. In fact, overlay of the Asp274 residues of the 1NM-PP1- (type I, PDB: 
4LGH) and ASDO2/6- (type II) bound structures illustrates another key difference between 
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type I and II inhibitors: The Asp residue flips 180o going from an active to an inactive 
conformation, allowing Phe to pack against ASDO6 (Figures 8A-B & S7D)19. 
 
In the ASDO6-bound structure, Cys210 appears to form a weak, electrostatic interaction with 
the amide ‘N’, and the Ala273 backbone carbonyl forms a strong hydrogen bond with the same 
amide group, serving as a molecular clamp that also brings to light the importance of the 
cysteine residue (Figure 8C). Comparing the ASDO2- and 6-bound structures also sheds light 
on the molecular level basis for the decrease in WT-kinase targeting by ASDO6; that ASDO6 
prefers binding to AAK only when the gatekeeper residue is a polar amino acid such as 
cysteine. Alignment of these structures shows that the methylphenyl ring of ASDO6 twists in 
the direction of Cys210, bringing the amide closer to the Ala273 backbone; however, a water 
molecule fills the gap between ASDO2, Cys210 and the Ala273 backbone with all three 
elements forming a hydrogen-bonding network in the ASDO2-bound structure (Figures 8D-E 
& S7E).  
 
As a result of placing the polar amide group of ASDO6 in closer proximity to the gatekeeper 
residue, WT AAK, which harbors a hydrophobic Leu210 gatekeeper residue, would disfavor 
and destabilize the ASDO6-bound conformation (Figure 8F). Based on this hypothesis, other 
hydrophobic amino acids such as Ala should also attenuate ASDO6 inhibitory activity and 
replacing cysteine with a less polar amino acid or with Gly, which lacks a side-chain, should 
abolish the molecular clamp mechanism and abrogate the ASDO6-GWL interaction as well. 
To test these hypotheses, we over-expressed, immunoprecipitated and treated FLAG-M110A-
GWL with ASDO6 up to a concentration of 10 M. As predicted, ASDO6 was not able to inhibit 
M110A-GWL, nor was 3MB-PP1 able to inhibit M110C-GWL in vitro (Figure 8G-H), suggesting 
the two systems work independently of each other and could be used to differentially inhibit 
other combinations of kinases based on gatekeeper mutations to either cysteine or Ala/Gly.  
 
Discussion and Conclusions 
AS-kinase technology has been employed to dissect the cellular functions of individual kinases 
across the kinase family, but there are still a number of kinases that remain averse to this 
methodology. In order to apply AS-kinase technology, mutations that engender sensitivity to 
pharmacologic inhibition must also maintain sufficient kinase activity so that the mutant kinase 
can recapitulate WT cellular function. There are many ways to broaden the scope of AS-kinase 
technology such as making sogg mutations that rescues the activity of ‘intolerant’ kinases 
when an Ala/Gly-gatekeeper mutation is present10. Also, over the years, a number of different 
AS- and ES-systems have been developed that incorporate amino acids other than Ala or Gly, 
e.g. Cys or Thr9, 13, 17, 18, into the gatekeeper position, but so far, these systems have not been 
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widely utilized in the field; though some are still in their infancy. In terms of AS-systems that 
have proven fruitful, a number of new reagents such as staralogs7 offer even greater specificity 
and potency, but to expand the scope of AS-kinase technology further we need not focus 
solely on engineering inhibitors against the active kinase conformation, but take full advantage 
of all modes of pharmacologic inhibition. To date, type II inhibitors have been left out of the 
loop when it comes to the development of chemogenomic technology, but this study is the first 
to provide an example of a chemical genetic system based on Cys-mutant kinase inhibition 
with a type II inhibitor; a system that we now refer to as the ASDO (Analog-Sensitive ‘DFG-
Out’)-kinase system (Figure 1B & C). 
 
Furthermore, type I and II kinase inhibitors bind to disparate kinase conformations resulting in 
their catalytic inactivation19, 27, 28. Due to evolutionary pressure to preserve the catalytically 
active kinase conformation, type I inhibitors encounter a very similar ATP-binding pocket 
across the kinome, made exploitable through the ‘bump-hole’ method. The inactive kinase 
conformation is not bound by this evolutionary pressure and is more varied28, which may have 
hampered previous attempts to generate a type II inhibitor-based ASDO-kinase system. 
Despite this variability, we systematically optimized the ASDO-scaffold to engender a small-
molecule inhibitor that displays generality across at least three divergent Ser/Thr-kinases 
bearing a Cys-gatekeeper, so far, and ASDO2/6 display bio-orthogonality versus WT kinases 
(Figures 1B & 4F). As this system not only appears to take advantage of steric 
complementarity, but also electrostatic interactions, to engender specificity toward Cys-
gatekeeper kinases, we hypothesized that it may act independently of the canonical AS-kinase 
system, which is based solely on steric complementarity. This theory was validated in vitro 
and will likely change the landscape of future studies involving signaling pathways in cells and 
disease models. These multiple AS/ASDO-kinase systems along with the Ele-Cys and ES-
kinase systems (systems that utilize electrophilic-quinazoline and 5’-electrophilic adenosine 
scaffolds) now provide an ensemble of chemical genetic tools to explore differential and 
independent kinase inhibition across at least two kinases in cells. 
 
Lastly, this system exploits binding to and stabilizing the ‘DFG-out’ conformation of kinases 
and we demonstrated the tenability of isolating these ASDO-co-crystal structures using X-ray 
crystallography. To date, X-ray crystal structures of inactive kinase conformations across the 
kinome are sparse19, 28, but the ASDO system could potentially be used to generate X-ray 
crystal structures of other inactive kinase conformations. This technology, therefore, has great 
potential to galvanize drug discovery efforts by providing new ‘DFG-out’ X-ray crystal 
structures that would assist with rational, in silico drug design efforts. 
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METHODS 
Kinase Assays 
Immunoprecipitation and radioactive kinase assays were carried out as published 
previously21. The catalytically dead mutant D174A-GWL was used as a control for inhibition. 
Aurora-A and xlCDK1 assays were carried out similarly to FLAG-GWL immunoprecipitation 
kinase assays. N-terminally tagged FLAG-Aurora-A32 kinase and C-terminally tagged MYC-
xlCDK1 were over-expressed in HEK 293T cells using the standard phosphate-mediated 
transfection method. Cdk1 assays were carried out by incubating HEK 293T lysates containing 
MYC-CDK1 with 4 g of anti-c-Myc antibody and immunoprecipitation with 5 l of 
Dynabeads™ Protein G (Thermofisher). To detect phosphorylated histones H1 (CDK1, Fig. 
S5A) and H3 (1g/20l reaction (AAK)) the standard kinase reaction was spiked with 0.075 
MBq -32P ATP (PerkinElmer) per 20 l reaction. After the reaction was stopped with 5 l 5X 
SDS loading buffer and boiled for 5 min at 95 °C, the mixture was resolved via SDS-PAGE (4-
15% Criterion pre-cast gels (Bio-Rad Laboratories) or 13% v/v SDS-polyacrylamide gels). 
Staining with coomassie-blue revealed ~28 and 21 kDa bands respectively that were imaged 
by autoradiography. All concentration-dependent kinase assays were performed thrice and 
quantitation of activity (Phospho-signal(radioactive/densitometry):kinase loading ratio) using 
ImageJ (1.47v) of the average normalized % kinase activity ± S.D. was plotted using Prism 
6.0. Non-linear regression using Prism 6.0 was used to calculate IC50 values.   
 
Crystallization and Data Collection 
Aurora-A (containing mutations L210C, C290A and C393A)31 was co-crystallized with ASDO2 
and ASDO6 by mixing purified protein (500 µM) with compound (ASDO2, 500 µM; ASDO6, 
1mM) in a 1:1 protein:ligand ratio, before setting up sitting-drop vapor diffusion experiments 
at 22 °C; where 0.25 μl of complex was mixed with 0.25 µl of crystallization buffer and 
equilibrated against a well volume of 50 µl.  
 
Crystals of Aurora-A bound to ASDO2 were obtained in condition F6 of the PEGs II Suite (0.2 
M ammonium sulfate, 0.1 M tri-sodium citrate pH 5.6, 25 % w/v polyethylene glycol 4000; 
Qiagen, USA) and bound to ASDO6 in condition A1 of the JCSG+ Suite (0.2 M lithium sulfate, 
0.1 M sodium acetate pH 4.5, 50 % w/v polyethylene glycol 400; Qiagen, USA). No additional 
cryo-protectant was added as the crystals were deemed already cryo-protected from their 
crystallization conditions. The crystals were cryo-cooled in liquid nitrogen and no ice formation 
was observed. Diffraction data to 2.4 Å (ASDO2) and 2.1 Å (ASDO6) resolution were collected 
at the Diamond Light Source [DLS, Didcot, UK] on beamline I04. 
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Phasing, Model Building and Refinement 
All diffraction data were collected at 100K. Autoprocessed datasets were generated by 
automatic integration of the data using the software package XDS followed by processing 
using the Pointless and Scala programs from the CCP4 software suite.   Phases were 
obtained by molecular replacement using Phaser with a high resolution structure of ADP-
bound Aurora-A C290A,C393A (PDB: 4CEG) used as the search model.  An iterative 
combination of manual building in Coot and refinement with Phenix.refine produced the final 
model: PDB codes 6HJK (ASDO2) and 6HJJ (ASDO6). The protein crystallized in 
spacegroups P3221 (ASDO2) and P6122 (ASDO6), with a single molecule comprising the 
asymmetric unit. Crystal data and structure refinement for ASDO2/6 can be found in 
Supplemental Tables 1 & 2.  
 
SUPPORTING INFORMATION 
Supplementary figures, tables and schemes, supplementary methods and characterization of 
synthetic compounds are supplied as supporting information. This material is available free of 
charge via the internet at http://pubs.acs.org. 
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FIGURE LEGENDS 
 
Figure 1. AS- and ASDO-kinase systems.  A) Tertiary structure of the Staurosporine-bound 
GWL domain with key features highlighted (PDB: 5LOH). B) Chemical structures of 1NM-PP1 
and ASDO2. C) Cartoon depicting a wild type kinase (top) with a bulky methionine gatekeeper 
residue. Mutating the gatekeeper residue to a smaller alanine (or glycine) residue generates 
an analog-sensitive (AS) kinase (middle). Mutating the gatekeeper residue to a cysteine 
generates an AS-kinase that is susceptible to inhibition by novel ‘DFG-out’ conformation-
targeting inhibitors (ASDOs; ASDO2 depicted here, bottom). The AS- and ASDO-kinase 
systems are orthogonal to wild type kinases and each other. D) A panel of reversible type I 
inhibitors that target alanine- or glycine-gatekeeper mutants. E) A panel of irreversible type I 
inhibitors that target cysteine mutations in the gatekeeper, hinge or G-loop regions. Structural 
features highlighted in BLUE complement the expanded hydrophobic pocket that is generated 
by mutation of the gatekeeper residue to alanine or glycine and features highlighted in RED 
represent cysteine-reactive, electrophilic warheads (fluoromethylketone, acrylamide and 
vinylsulfone). 
 
Figure 2. Systematic mutational analysis of the GWL gatekeeper position. A) General 
workflow for the immunoprecipitation-mediated kinase assay. B,C) Systematic analysis of 
gatekeeper mutations in the GWL ATP-binding pocket. D) Rescue of RNAi-mediated GWL 
depletion by co-expression with siRNA-resistant WT- and MC-GWL constructs (pWTr and 
pMCr). E-I) FACS-cell cycle analysis of HeLa cells.  Kinase assays were performed at least 
3-times per mutation and quantitation using ImageJ (1.47v) (densitometry) of the average 
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normalized % kinase activity (pENSA:GWL ratio used as a readout of kinase activity) ± S.D. 
was performed and plotted using Prism 6.0. 
 
Figure 3. Establishing the inhibitory activity of AD57 and ASDO1 in the GWL kinase 
assay.  A) Chemical Structures of AD57 and ASDO1. Structural features highlighted in Green 
are linkers that bridge the PP1 moiety with the terminal trifluoromethylphenyl (Red) group.  B-
C) FLAG-tagged WT- and MC-GWL kinase assays in the presence of increasing 
concentrations of AD57 (B) or ASDO1 (C). D) Kinase activity was quantitated using ImageJ 
(1.47v) (densitometry) and reported as the average normalized % kinase activity ± S.D. 
 
Figure 4. In vitro analysis of ASDO-derivatives. A) The potency of synthetic AD57-
derivatives (ASDOs), DO1 and commercially available DO2 was assessed using an in vitro 
immunoprecipitation kinase assay; na = not applicable and nd = not determined. The 
potencies of  ASDO2 (B-C) and ASDO6 (C-D) were determined using FLAG-tagged WT- and 
MC-GWL kinase assays. E) ASDO2 and ASDO6 were screened at 1M against a panel of 50 
kinases, carefully selected to represent the kinome, using the Kinase Express Screen 
(International Centre for Kinase Profiling, University of Dundee). 
 
Figure 5. In vitro analysis of ASDO2/6 in FLAG-AAK and Myc-Cdk1 kinase assays. The 
inhibitory activity of ASDO2 (A&C) & ASDO6 (B-C) against FLAG-tagged WT- and LC-AAK 
constructs was assessed using a radioactive kinase assay to detect 32PO4-H3 substrate. D-E) 
The inhibitory activity of ASDO6 against MYC-tagged WT and F80C-Cdk1 was assessed 
using a radioactive kinase assay for the detection of 32PO4-H1. C,F) Kinase activity was 
quantitated using ImageJ (1.47v) (densitometry) and reported as the average normalized % 
kinase activity ± S.D.  
 
Figure 6. Cellular analysis of ASDO2 in WT- and MC-GWL expressing mouse embryonic 
fibroblasts (MEFs). A) Expression of exogenous WT- and MC-GWL confirmed by western 
analysis. B) Strategy used to fully activate GWL in MEFs. Cells were treated with 200 ng/mL 
nocodazole for 16 – 20 h before harvesting for downstream applications. C-D) Mitotic cells 
were treated with 2M ASDO2 or DMSO for 4 h. ENSA, phospho-ENSA and tubulin levels in 
cell lysates were determined by western analysis. All experiments were repeated thrice and 
activity (pENSA:ENSA ratio) was quantitated using ImageJ (1.47v) (densitometry), normalized 
to DMSO control and reported as the average fold induction relative to DMSO control (without 
nocodazole) ± S.D. E) CellTiter Blue Proliferation assays. 
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Figure 7. Comparing binding kinetics of ASDO2 to type I/II kinase inhibitors 
staurosporine (STP, type I) and AD57 (type II).  FLAG-tagged MC-GWL was treated with 
DMSO (A – F), ASDO2 (A,C & D), STP (B,C) or AD57 (E) for 20 minutes and then subjected 
to GWL kinase assay conditions. These beads were also subjected to several washes (buffer 
exchange) for the indicated amount of time before start of the kinase assay (A – F).  F) Kinases 
assays were performed with FLAG-tagged MC-GWL, pre-incubated with DMSO or ASDO2 for 
20 or 60 m before start of the kinase reaction; reaction started by addition of ATP and ENSA. 
All experiments were repeated thrice and the average pENSA/FLAG(M110C-GWL) ratio was 
quantitated using ImageJ (1.47v) (densitometry) and normalized to DMSO control (C). 
 
Figure 8. X-ray co-crystal structures of ASDO2 and ASDO6 with LC Aurora-A kinase. A)  
Alignment of ASDO6 (6HJJ), ADP (4CEG) and 1NM-PP1 (4LGH) bound structures reveals 
the orientation of their respective catalytic-motif aspartic acid residues. B) A zoomed-in view 
of panel (A). C) ASDO6 abuts the gatekeeper cysteine residue forming a weak electrostatic 
interaction with the thiol hydrogen of cysteine and a stronger hydrogen-bonding interaction 
with the backbone of Ala273, serving to clamp ASDO6 within the nucleotide binding-site 
proximal to the gatekeeper position. D) Comparison of the ASDO2- and ASDO6-bound LC-
AAK structures. E) A zoomed-in view of panel (D). F) Superimposition of the ASDO6- and 
ADP-bound structures reveals a potential conflict between the ASDO6-amide and the 
hydrophobic L210 gatekeeper residue. G,H) ASDO6 (G) and 3MB-PP1 (H) inhibitory activity 
was assessed against M110A-GWL and MC-GWL respectively using the immunoprecipitation 
kinase assay. 
 
 
 
 
 
 
 
 
 
